SCHEMBL30121085

SCHEMBL30121085

Cc1nc2cc(O)ccc2c(-c2ccccc2)c1C(C)C

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 5/20 0.55
ESR2 Q92731 5/20 0.55
GAA P10253 1/20 0.42
MAPT P10636 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
SMN1; SMN2 Q16637 3/20 0.41
ERAP1 Q9NZ08 2/20 0.40
ALDH1A1 P00352 2/20 0.40
KDM4E B2RXH2 1/20 0.40
FABP3 P05413 1/20 0.39
FABP4 P15090 1/20 0.39
PRNP P04156 1/20 0.39
PPARG P37231 1/20 0.39
RXFP1 Q9HBX9 1/20 0.39
NR2E3 Q9Y5X4 1/20 0.39
NCOR2 Q9Y618 1/20 0.39
MEN1 O00255 1/20 0.38
LMNA P02545 1/20 0.38
KMT2A Q03164 1/20 0.38
TACR3 P29371 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23896383 1.00 ESR1 (0.55) ESR1ESR2GAAMAPTNPSR1
SCHEMBL23887859 0.86 KDM4E (0.42) ESR1ESR2MAPTKDM4E
SCHEMBL30121046 0.86 KDM4E (0.42) ESR1ESR2MAPTKDM4E
SCHEMBL23887749 0.82 TLR8 (0.38) ESR1ESR2
SCHEMBL23887701 0.77 TRPV1 (0.37) ESR1ESR2GAAMAPTERAP1
SCHEMBL30120959 0.77 TRPV1 (0.37) ESR1ESR2GAAMAPTERAP1
SCHEMBL23887706 0.72 ESR1 (0.39) ESR1ESR2MAPTKDM4E
SCHEMBL30367719 0.72 ESR1 (0.39) ESR1ESR2MAPTKDM4E
SCHEMBL7127697 0.69 GPR3 (0.50) GAAMAPTNPSR1ALDH1A1KDM4E
SCHEMBL23887908 0.69 MAPK14 (0.44) MAPTNPSR1SMN1; SMN2ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4126819-A1 7- OR 8-HYDROXY-ISOQUINOLINE AND 7- OR 8-HYDROXY-QUINOLINE DERIVATIVES AS ALPHA-1 -ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1 -ANTITRYPSIN DEFICIENCY (AATD) Vertex Pharmaceuticals Incorporated (US) 2023-02-08 EP disclosed